Health Technology · Pharmaceuticals: Major · NSE: DCAL · data 2026-10-09
Dishman Carbogen Amcis Ltd.
Health check: Weak (3.3/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹149.68
Market cap
₹2,301 cr
P/E
34.4
P/B
—
ROE
1.6%
ROCE
2.6%
Debt / equity
0.46
Dividend yield
0.00%
1-year return
-48.4%
52-week high
₹303
52-week low
₹128.5
Operating margin
7.1%
Growth
| Revenue (last 12 months) | ₹2,292 cr |
| Net profit (last 12 months) | ₹68 cr |
| Sales growth, 3 years (yearly) | 7.6% |
| Profit growth, 3 years (yearly) | — |
Chart patterns
- Double top — breakdown (key level ₹176.1)
Similar companies
Venus Remedies Limited (VENUSREM) · Syncom Formulation (India) Ltd. (SYNCOMF) · Sai Parenterals Limited (SAIPARENT) · Sakar Healthcare Ltd (SAKAR) · Indoco Remedies Limited (INDOCO)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open DCAL in NSE Scanner →